BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CT-P53 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CT-P53\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05906992-7343@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:CT-P53: Phase 3 readout est. (NCT05906992)
DESCRIPTION:CT-P53\, phase 3\, Multiple Sclerosis.\nStudy: A Study to Compa
 re Efficacy\, Pharmacokinetics\, Pharmacodynamics and Safety of CT-P53 and
  Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis\nEstimate
 d primary completion: February 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ct-p53#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05906992
URL:https://assetmemo.bio/drug/ct-p53#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
